• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

EPAD launches largest ever pre-dementia cohort

2016-03-21News

On 21 March, between 40 and 50 representatives of the European Prevention of Alzheimer’s Dementia (EPAD) project met in Edinburgh, to launch the largest ever specific pre-dementia cohort. Participants at the “1st wave Investigator meeting” included representatives from Clinical Research Organisations (CROs) and six dedicated teams from France, Italy, the Netherlands, Spain, Sweden, Switzerland and the UK. The objective of the meeting, which took place at St Leonard’s Hall, was to prepare attendees from trial delivery centres (TDCs) to put the EPAD Longitudinal Cohort Study (LCS) into action.

Day one of the two-day meeting mainly focused on explaining how the LCS works conceptually. Tony Brooks, Graciela Muniz Terrera and Craig Ritchie amongst others explained the purpose of the protocol and how the LCS is different from other cohort studies. Ray French also spoke about the role and responsibilities of ACCORD (The Academic and Clinical Central Office for Research and Development – a partnership between the University of Edinburgh and NHS Lothian Health Board) in the LCS, and Judi Syson closed the first day of the meeting with a few words on progress m

On 21 March, between 40 and 50 representatives of the European Prevention of Alzheimer’s Dementia (EPAD) project met in Edinburgh, to launch the largest ever specific pre-dementia cohort. Participants at the “1st wave Investigator meeting” included representatives from Clinical Research Organisations (CROs) and six dedicated teams from France, Italy, The Netherlands, Spain, Sweden, Switzerland and The UK. The objective of the meeting, which took place at St Leonard’s Hall, was to prepare attendees from trial delivery centres (TDCs) to put the EPAD Longitudinal Cohort Study (LCS) into action.

Day one of the two-day meeting mainly focused on explaining how the LCS works conceptually. Tony Brooks, Graciela Muniz Terrera and Craig Ritchie amongst others explained the purpose of the protocol and how the LCS is different from other cohort studies. Ray French also spoke about the role and responsibilities of ACCORD (The Academic and Clinical Central Office for Research and Development – a partnership between the University of Edinburgh and NHS Lothian Health Board) in the LCS, and Judi Syson closed the first day of the meeting with a few words on progress made with the Ethics Committee (EC) approvals for the different sites.

Day two focused on the truly operational aspects of the project, and included training for all site personnel on monitoring and data management (Quintiles) sample handling (The Roslin Institute), the procedure for taking and processing MRI images (IXICO) and how cognitive tests work, including a hands-on session using tablets (Medavante). To close the day, a few words were said by Mila Etropolski from WP4, on how the LCS will continue into the Proof-of-Concept (PoC) study.

Lisa Vermunt, based at the VU University Medical Center Amsterdam (VUMC), is involved in WP3, helping to set up the EPAD Register and the TDC in Amsterdam. “Since the beginning I am looking forward to the start of the cohort – actually seeing participants for our investigations – and now we are really almost there!” she enthused after attending the Edinburgh meeting.

Samuel Rabanaque, based at the Fundación Pasqual Maragall, is mainly working on WP4 and will be involved in running the trial at the Barcelona site. “The Investigator meeting allowed us to review in a concentrated way all materials and procedures involving EPAD-LCS protocol. Besides, it gave us the opportunity to share our doubts and expectations with colleagues from other centres”, he said.

The goal of the EPAD initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities) who still may have little or no complaints or clinical symptoms. EPAD’s European-wide cohort will consist of over 6,000 participants, of which 1,500 will be invited to participate in a trial to test new treatments for the prevention of Alzheimer’s dementia. The five year programme is part of the Innovative Medicines Initiative.

Follow EPAD on Twitter @IMI_EPAD and keep up to date with the cohort via the hashtag #EPADCohort.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Neuronet releases its Knowledge Base dashboard
2021-02-01
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
Latest News
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
  • Local actions to keep the EPAD Longitudinal Cohort data collection going
    2021-02-17
  • Neuronet releases its Knowledge Base dashboard
    2021-02-01
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

The latest @AlzheimerEurope #newsletter includes an article on the first local @IMI_EPAD community meeting held last month among the Scottish research sites and collaborators who have been involved in the EPAD Longitudinal Cohort Study. Read more here: bit.ly/Feb2021AEnews twitter.com/AlzheimerEurop…

reply retweet favorite
3:26 pm · 2021-03-03
Twitter
EPAD
EPAD
@IMI_EPAD

@AD_PREVENT @alzassociation @alzheimerssoc Congratulations to all the team 👏

reply retweet favorite
7:03 am · 2021-03-01
Twitter
EPAD
EPAD
@IMI_EPAD

.@AlzheimerEurope has published a new edition of its “Dementia in Europe” magazine. It includes a closing article on @IMI_EPAD. Our co-leads @craig_ritchie68 and Serge Van der Geyten, reflect on the achievements of the project. Download the PDF here: bit.ly/DementiaInEuro… twitter.com/AlzheimerEurop…

reply retweet favorite
12:40 pm · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Last week, we held the first local @IMI_EPAD community meeting among the Scottish research sites, collaborators, academics & scientists who have been involved in our Longitudinal Cohort Study and now continue to contribute to the study locally More info⤵️ ep-ad.org/2021/02/17/loc… pic.twitter.com/MTKmanCURk

reply retweet favorite
6:51 am · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the new @AlzheimerEurope report on #DataSharing in #dementia #research, which reviews recent changes in EU research policy and sets out recommendations to improve data sharing. It includes case studies from ADNI, @IMI_EPAD and @IMI_EMIF. ⬇️ Bit.ly/DataSharing_AE twitter.com/AlzheimerEurop…

reply retweet favorite
2:39 pm · 2021-02-23
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.